All Stories

  1. Quantitative AI yields algorithmic RNA biomarkers from a rheumatoid arthritis clinical trial, accurately predicting individual patient responses to anti-TNF treatment, providing a novel approach to companion diagnostic discovery.   
  2. Distinct natural killer cell signature in still's disease: Insights from a multinational immunome project consortium for autoinflammatory disorders
  3. Quantitative AI yields algorithmic RNA biomarkers from a rheumatoid arthritis clinical trial, accurately predicting individual patient responses to anti-TNF treatment, providing a novel approach to companion diagnostic discovery.   
  4. Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort
  5. Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult‐Onset Still's Disease
  6. FACS-based detection of extracellular ASC specks from NLRP3 inflammasomes in inflammatory diseases
  7. Inflammatory profile of lower risk myelodysplastic syndromes
  8. A nosology of immune diseases from deep immunophenotyping
  9. Novel Targeted Therapies for Rheumatoid Arthritis Based on Intracellular Signalling and Immunometabolic Changes: A Narrative Review
  10. Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for Romiplostim
  11. Inhibition of IRE1 RNase activity modulates tumor cell progression and enhances the response to chemotherapy in colorectal cancer
  12. Steroid hormone catabolites activate the pyrin inflammasome through a non-canonical mechanism
  13. Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming
  14. RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients
  15. Inflammasome activation: from molecular mechanisms to autoinflammation
  16. An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 Mutation Enhancing Binding to NEK7
  17. Neurodegenerative Disease and the NLRP3 Inflammasome
  18. Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study
  19. Identification of Critical Transcriptomic Signaling Pathways in Patients with H Syndrome and Rosai-Dorfman Disease
  20. Inflammasome inhibition under physiological and pharmacological conditions
  21. COVID-19 meets Cystic Fibrosis: for better or worse?
  22. WS12.6 Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis
  23. Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations
  24. Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis
  25. Moving towards a systems-based classification of innate immune-mediated diseases
  26. TRAP1 chaperone protein mutations and autoinflammation
  27. ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis
  28. Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1α Arm of the Unfolded Protein Response Results in Exacerbated Inflammation
  29. ePS1.09 Inhibition of autoinflammation in cystic fibrosis using small molecule therapy
  30. TNF receptor signalling in autoinflammatory diseases
  31. Tumour necrosis factor signalling in health and disease
  32. S138 Inhibition of auto-inflammation in cystic fibrosis using small molecule therapy
  33. Excessive ENaC-mediated sodium influx drives NLRP3 inflammasome-dependent autoinflammation in cystic fibrosis
  34. Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data
  35. Poster Session Abstracts
  36. ER Stress: A Therapeutic Target in Rheumatoid Arthritis?
  37. Cellular stress, with activation of unfolded protein response (UPR) and microRNA, in disease.
  38. WS04.3 Sodium influx modulates innate immune inflammation and metabolism in cystic fibrosis
  39. Innate immune driven inflammation in the lung
  40. Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down‐Regulation of Axin‐2
  41. P043 Investigating IL-6 intracellular signalling in peripheral blood cell subsets in patients at early and later stages of rheumatoid arthritis (RA)
  42. Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide
  43. Erratum: The RA-MAP Consortium: a working model for academia–industry collaboration
  44. The RA-MAP Consortium: a working model for academia–industry collaboration
  45. Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis
  46. 78 Inflammasome activation in cystic fibrosis bronchial epithelial cells is exacerbated in hypoxia
  47. 03.24 Effect of tocilizumab therapy on il-6 signalling pathway in early rheumatoid arthritis patients
  48. Lessons from characterization and treatment of the autoinflammatory syndromes
  49. Corticosteroid transdermal delivery significantly improves arthritis pain and functional disability
  50. Protection against lupus-like inflammatory disease is in the LAP of non-canonical autophagy
  51. The burgeoning field of innate immune-mediated disease and autoinflammation
  52. Autoinflammatory diseases: update on classification diagnosis and management
  53. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology
  54. A2.40 Investigating IL-6 pathway signalling kinetics in peripheral blood single cell subsets with tocilizumab therapy in patients with early rheumatoid arthritis
  55. Faculty of 1000 evaluation for In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity.
  56. Faculty of 1000 evaluation for Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis.
  57. OP0309 Identification of A Predictive Microrna Signature of Progression from Pre-RA Systemic Autoimmunity to Development of RA Using Matched Serum Samples
  58. SAT0552 Response to Anakinra is Effective for the Diagnosis and Treatment of Systemic Autoinflammatory Disorder of Unknown Genetic Cause
  59. Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond
  60. Biological Therapies in Osteoarthritis
  61. A7.2 Identification of predictive micro-RNAs of progression from PRE-RA systemic autoimmunity to development of RA using matched serum samples
  62. Monogenic autoinflammatory diseases
  63. Clinical genetics in 2014: New monogenic diseases span the immunological disease continuum
  64. E. Chester Ridgway, MD, MACP (1942–2014)
  65. The Clinical Endocrinology Workforce: Current Status and Future Projections of Supply and Demand
  66. Clinical Realization of Sector Beam Intensity Modulation for Gamma-Ray Based Radiosurgery
  67. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future
  68. SU-D-16A-06: Modeling Biological Effects of Residual Uncertainties For Stereotactic Radiosurgery
  69. TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes
  70. Impact of Millimeter-Level Margins on Peripheral Normal Brain Sparing for Gamma Knife Radiosurgery
  71. (252) Adherence to CONSORT and ACTTION guidelines for adverse event reporting in non-pharmacologic, non-interventional analgesic clinical trials: ACTTION systematic review and recommendations
  72. IL-17A RNA Aptamer: Possible Therapeutic Potential in Some Cells, More than We Bargained for in Others?
  73. A1.52 TLR-Dependent XBP1 activation induces an autocrine loop in rheumatoid arthritis synovial fibroblasts
  74. Faculty Opinions recommendation of CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy.
  75. Correction: First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
  76. First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
  77. Use of gevokizumab for the treatment of Behçet's disease
  78. Small intestinal mucosal xanthoma in a patient with CHILD syndrome
  79. OP0074 First Report of Circulating Micrornas in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
  80. SP0050 The Spectrum of NLR AND Related Molecules in Human Disease
  81. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment
  82. Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene
  83. OR10-002 - A novel TNFR1 transcript of TRAPS gene
  84. OR10-004 - Circulating micrornas in TRAPS
  85. PW02-013 - The role of IL6 and LPS in pathogenesis of TRAPS
  86. Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome
  87. Reliability of contour-based volume calculation for radiosurgery
  88. High-precision volume-staged Gamma Knife surgery and equivalent hypofractionation dose schedules for treating large arteriovenous malformations
  89. How Millimeter Margins Impact RTOG9005 Tolerance Dose Levels for Intracranial Stereotactic Radiosurgery
  90. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients
  91. Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives
  92. SP0075 Autoimmunity and autoinflammation - oppositive sides of the same coin
  93. OP0256 Involvement of unfolded protein response and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor- associated periodic syndrome (TRAPS)
  94. SU‐D‐211‐04: Sector Intensity Modulated (SIM) Gamma Knife Stereotactic Radiosurgery
  95. PTU-116 Expression of NLRP3 inflammasome proteins in normal and Crohn's disease colon: Abstract PTU-116 Table 1
  96. Clinical Presentation of and Outcome for Solitary Rectal Ulcer Syndrome in Children
  97. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients
  98. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases
  99. Cerebellum volume in high-risk offspring from multiplex alcohol dependence families: Association with allelic variation in GABRA2 and BDNF
  100. Shot sequencing based on biological equivalent dose considerations for multiple isocenter Gamma Knife radiosurgery
  101. Anti-TNF Treatment in Rheumatoid Arthritis
  102. Clinical Outcome and Prognostic Factors for Central Neurocytoma
  103. Is caspase 1 central to activation of interleukin-1?
  104. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome
  105. The role of the NLRP3 inflammasome in gout
  106. The early phase of psoriatic arthritis
  107. Inflammasomes and autoimmunity
  108. Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients
  109. Primitive Myxoid Mesenchymal Tumor of Infancy: A Report of a Further Case with Locally Aggressive Behavior
  110. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes
  111. Lessons from Anti-TNF Biologics: Infliximab Failure in a TRAPS Family with the T50M Mutation in TNFRSF1A
  112. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan
  113. P3.52 FOR-DMD: double-blind randomized trial to optimize steroid regime in Duchenne Muscular Dystrophy (DMD)
  114. Corrigendum
  115. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients
  116. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes
  117. Temperament at 5years of age predicts amygdala and orbitofrontal volume in the right hemisphere in adolescence
  118. Concurrent Oral 4 - Basic Science [OP24-OP31]: OP24. Hdac Activity: A Therapeutic Target in Rheumatoid Arthritis?
  119. The NLRP3 inflammasome, a target for therapy in diverse disease states
  120. A case of congenital solitary Langerhans cell histiocytoma
  121. Periodic fever syndrome and autoinflammatory diseases
  122. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
  123. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
  124. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
  125. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
  126. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
  127. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics
  128. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
  129. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline
  130. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
  131. P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study
  132. Comparison of autoinflammation and autoimmunity using TRAPS and rheumatoid arthritis as prototypes of these conditions
  133. Imaging evidence for persistent subclinical fasciitis and arthritis in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) between febrile attacks
  134. Inflammation: Canakinumab for the cryopyrin-associated periodic syndromes
  135. Effects of Gabapentin on Sleep in Menopausal Women with Hot Flashes as Measured by a Pittsburgh Sleep Quality Index Factor Scoring Model
  136. p38MAPK: stress responses from molecular mechanisms to therapeutics
  137. Proteolytic Activation of the Cytotoxic Phenotype during Human NK Cell Development
  138. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response
  139. An Integrated Classification of Pediatric Inflammatory Diseases, Based on the Concepts of Autoinflammation and the Immunological Disease Continuum
  140. The Importance of Specific Education for Asthma Patients Discharged from the Emergency Department and Hospital
  141. A SCIENCE OF INTENTION
  142. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome
  143. Rilonacept in the treatment of chronic inflammatory disorders
  144. Disruption of Orbitofrontal Cortex Laterality in Offspring from Multiplex Alcohol Dependence Families
  145. Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) or Familial Hibernian Fever
  146. Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism
  147. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
  148. T.P.5.03 Equipoise concerning corticosteroid use in boys with Duchenne muscular dystrophy: persistent wide variations in practice
  149. Complications of Lumboperitoneal Shunts
  150. Psychopathology in offspring from multiplex alcohol dependence families with and without parental alcohol dependence: A prospective study during childhood and adolescence
  151. Reply
  152. Fifth International Congress on Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
  153. Cryptogenic, Multifocal, Ulcerous, and Stenosing Enteritis as a Manifestation of Enterocolic Venopathy
  154. Evolution of major histocompatibility complex by “en bloc” duplication before mammalian radiation
  155. The FDA Revises Requirements for Levothyroxine Products
  156. The asthma emergency department visit: treating a crisis in the midst of uncontrolled disease
  157. The Feasibility of Using a Web-based Tool to Implement a Regional Emergency Department Surveillance of Asthma Care
  158. Successful treatment of resistant pseudogout with anakinra
  159. Primer: inflammasomes and interleukin 1β in inflammatory disorders
  160. NOD-like receptors and inflammation
  161. Use of Anakinra (Kineret) in the Treatment of Familial Cold Autoinflammatory Syndrome with a 16-Month Follow-Up
  162. A novel TNFRSF1A splice mutation associated with increased nuclear factor  appaB (NF- B) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS)
  163. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra
  164. fMRI BOLD Response to the Eyes Task in Offspring From Multiplex Alcohol Dependence Families
  165. Potential Value of MR Spectroscopic Imaging for the Radiosurgical Management of Patients with Recurrent High-Grade Gliomas
  166. G.P.2.01 The natural history of spinal muscular atrophy – preliminary results from the PNCR network
  167. The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self
  168. The NLR-related disorders
  169. From inflammasomes to fevers, crystals and hypertension: how basic research explains inflammatory diseases
  170. Anatomic Landmarks Versus Fiducials for Volume-Staged Gamma Knife Radiosurgery for Large Arteriovenous Malformations
  171. Gastric Epithelial Siderosis in Acute Lymphoblastic Leukemia
  172. Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor–associated periodic syndrome
  173. Investigation of the role of the p38 MAPK α and δ isoforms in nonresponse to tumour necrosis factor blockade in the synovium of rheumatoid arthritis patients
  174. Failure of cutting balloon angioplasty to prevent restenosis in childhood pulmonary venous stenosis
  175. N.P.4 02 Motor function measure that permits the evaluation of ambulatory spinal muscular atrophy patients
  176. Are Plans Necessary?
  177. A Proposed Classification of the Immunological Diseases
  178. Successful Surgical Resection of Intrapericardial Extralobar Pulmonary Sequestration With Congenital Pulmonary Adenomatoid Malformation Type II
  179. Hereditary auto-inflammatory disorders and biologics
  180. Gene expression and angiotropism in primary CNS lymphoma
  181. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism
  182. Improving Pediatric Asthma Care Through Surveillance: The Illinois Emergency Department Asthma Collaborative
  183. Adequacy of Medical Chart Review to Characterize Emergency Care for Asthma: Findings from the Illinois Emergency Department Asthma Collaborative
  184. the tumour necrosis factor receptor-associated periodic syndrome: current concepts
  185. Anatomic Landmarks vs Fiducials for Staged Gamma Knife Radiosurgery for Large Arteriovenous Malformations
  186. Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation
  187. TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study
  188. The EIF2AK3 gene region and type I diabetes in subjects from South India
  189. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement
  190. A common pathway in periodic fever syndromes
  191. The continuing decline of autopsies in clinical trials: is there any way back?
  192. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis
  193. The major histocompatibility complex origin
  194. NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
  195. Periodic fever due to a novel TNFRSF1A mutation in a heterozygous Chinese carrier of MEFV E148Q
  196. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease
  197. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra
  198. Infevers: An evolving mutation database for auto-inflammatory syndromes
  199. Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study
  200. Treatment of Progressive or Recurrent Glioblastoma Multiforme in Adults with Herpes Simplex Virus Thymidine Kinase Gene Vector-Producer Cells Followed by Intravenous Ganciclovir Administration: A Phase I/II Multi-Institutional Trial
  201. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes
  202. Interleukin-1–Receptor Antagonist in the Muckle–Wells Syndrome
  203. Modeling generalized parton distributions to describe deeply virtual Compton scattering data
  204. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment
  205. Genetic clues to understanding periodic fevers, and possible therapies
  206. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept
  207. The autoinflammatory syndromes
  208. SPINK1 Is a Susceptibility Gene for Fibrocalculous Pancreatic Diabetes in Subjects from the Indian Subcontinent
  209. Association of mutations in theNALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis
  210. Cytokine gene polymorphism in human disease: on-line databases, Supplement 2
  211. Genetics of type 1 diabetes mellitus
  212. Vitamin D Receptor (VDR) mRNA and VDR Protein Levels in Relation to Vitamin D Status, Insulin Secretory Capacity, and VDR Genotype in Bangladeshi Asians
  213. Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial
  214. A novel mutation in the third extracellular domain of the tumor necrosis factor receptor 1 in a Finnish family with autosomal-dominant recurrent fever
  215. Genetic susceptibility to fibrocalculous pancreatic diabetes in Bangladeshi subjects: a family study
  216. An Israeli Arab patient with a de novoTNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome
  217. Hereditary periodic fever syndromes
  218. Complex branchial fistula: A variant arch anomaly
  219. Cytokine gene polymorphism in human disease: on-line databases, Supplement 1
  220. Tumour necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families
  221. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: evidence for a TNFRSF1A mutation with reduced penetrance
  222. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
  223. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors
  224. Prophylactic Thyroidectomy in the Treatment of Thyroid Medullary Carcinoma. Age for Surgery?
  225. An autosomal dominant periodic fever associated with AA amyloidosis in a North Indian family maps to distal chromosome 1q
  226. TNFRSF1A mutations and autoinflammatory syndromes
  227. Family association studies of markers on chromosome 2q and Type 1 diabetes in subjects from South India
  228. Pancreatitis in fibrocalculous pancreatic diabetes mellitus is not associated with common mutations in the trypsinogen gene
  229. Asthma Care Practices in Chicago-Area Emergency Departments
  230. Evaluating the Outcome of Two Teaching Methods of Breath Actuated Inhaler in an Inner City Asthma Clinic
  231. The Chicago Emergency Department Asthma Collaborative
  232. Cytokine gene polymorphism in human disease: on-line databases
  233. Comparison of Two Regimens of β-Adrenergics in Acute Asthma
  234. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes
  235. The MHC Big Bang
  236. B30.2-like domain proteins: update and new insights into a rapidly expanding family of proteins
  237. Linkage of Familial Hibernian Fever to Chromosome 12p13
  238. Exclusion of the familial Mediterranean fever locus as a susceptibility region for autosomal dominant familial Hibernian fever.
  239. Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians
  240. Emergency Department Observation Unit Versus Hospital Inpatient Care for a Chronic Asthmatic Population
  241. Prediction of Relapse within Eight Weeks after an Acute Asthma Exacerbation in Adults
  242. Modelling the major histocompatibility complex susceptibility to RA using the MASC method
  243. Costs of an Emergency Department—Based Accelerated Diagnostic Protocol vs Hospitalization in Patients With Chest Pain
  244. A Comparison Between Emergency Diagnostic and Treatment Unit and Inpatient Care in the Management of Acute Asthma
  245. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy
  246. Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians
  247. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment
  248. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder
  249. NO LINKAGE OR ASSOCIATION OF TELOMERIC AND CENTROMERIC T‐CELL RECEPTOR β‐CHAIN MARKERS WITH SUSCEPTIBILITY TO TYPE 1 INSULIN‐DEPENDENT DIABETES IN HLA‐DR4 MULTIPLEX FAMILIES
  250. Multiple Sclerosis
  251. The Role of T‐Cell Receptor β Chain Genes in the Susceptibility to Rheumatoid Arthritis
  252. Non-linkage of a T-Cell Receptor γ Chain Microsatellite ( D7S485 ) to Rheumatoid Arthritis in Multiplex Families
  253. Moderate versus restrictive diets: Implications for relapse
  254. The role of t cell receptor β chain genes in susceptibility to rheumatoid arthritis
  255. Aminophylline in the Treatment of Acute Asthma When ß2-Adrenergics and Steroids Are Provided
  256. Emergency Department Treatment of Severe Asthma
  257. Multiple Sclerosis Susceptibility. Population and Twin Study of Polymorphisms in the T-Cell Receptor β and γ Genes Region
  258. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge- eaters
  259. Psychiatric disorders among obese binge eaters
  260. Irradiation and CCNU in Glioma Therapy
  261. Antibodies to Epstein-Barr viral antigens in familial rheumatoid arthritis
  262. A Molecular Basis for MHC Class II—Associated Autoimmunity
  263. Systemic vasculitis in a rheumatology unit over a two year period
  264. INSULIN TREATMENT OF DIABETIC KETOACIDOSIS
  265. Abstract